TY - JOUR
T1 - Peptide epitope identification for tumor-reactive CD4 T cells
AU - Kobayashi, Hiroya
AU - Celis, Esteban
N1 - Funding Information:
This work was supported by NIH grants P50CA91956, R01CA80782 and R01CA103921 (E. Celis) and Ministry of Education, Sports, and Culture of Japan grant-in-aid 18590360 (H. Kobayashi).
PY - 2008/4
Y1 - 2008/4
N2 - Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.
AB - Because T lymphocytes have the capacity to recognize tumor cells, significant efforts are being devoted towards the development of T cell-based immunotherapy for cancer. Most of this work has centered in the induction of anti-tumor CD8 T cells, which exhibit cytolytic activity towards tumor cells expressing tumor-specific or tumor associated antigens. Unfortunately to this day, T cell-based immunotherapy for cancer remains suboptimal. One of the possible explanations is that these immunotherapies have ignored the role that CD4 T helper lymphocytes play in the generation and persistence of CD8 T cell responses. Thus, we believe that in order to obtain clinical benefits T cell-based immunotherapy must stimulate both CD8 and CD4 tumor-reactive T cell responses. During the past seven years our group has focused on the identification of CD4 T cell epitopes from tumor-associated and tumor-specific antigens that could be used to complement the already identified CD8 T cell epitopes to produce effective vaccination strategies against numerous tumor types. We will describe here the strategy we used that resulted in the identification and characterization of numerous CD4 T cell epitopes that are applicable to developing therapies against hematological malignancies and solid tumors.
UR - http://www.scopus.com/inward/record.url?scp=44749086558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44749086558&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2008.04.011
DO - 10.1016/j.coi.2008.04.011
M3 - Review article
C2 - 18499419
AN - SCOPUS:44749086558
SN - 0952-7915
VL - 20
SP - 221
EP - 227
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
IS - 2
ER -